Karyopharm Therapeutics Inc (NASDAQ: KPTI) on Monday, soared 8.81% from the previous trading day, before settling in for the closing price of $0.83. Within the past 52 weeks, KPTI’s price has moved between $0.62 and $1.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 52.21% over the past five years. The company achieved an average annual earnings per share of 40.46%. With a float of $114.06 million, this company’s outstanding shares have now reached $114.92 million.
Let’s look at the performance matrix of the company that is accounted for 325 employees. In terms of profitability, gross margin is 95.86%, operating margin of -89.89%, and the pretax margin is -61.53%.
Karyopharm Therapeutics Inc (KPTI) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Karyopharm Therapeutics Inc is 8.52%, while institutional ownership is 54.17%. The most recent insider transaction that took place on Oct 04 ’24, was worth 3,172. In this transaction President and CEO of this company sold 3,607 shares at a rate of $0.88, taking the stock ownership to the 1,135,607 shares. Before that another transaction happened on Sep 04 ’24, when Company’s SVP, General Counsel&Secretary sold 3,971 for $0.72, making the entire transaction worth $2,866. This insider now owns 273,881 shares in total.
Karyopharm Therapeutics Inc (KPTI) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 40.46% per share during the next fiscal year.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Karyopharm Therapeutics Inc (KPTI) is currently performing well based on its current performance indicators. A quick ratio of 3.56 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.67 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc (NASDAQ: KPTI) saw its 5-day average volume 0.34 million, a negative change from its year-to-date volume of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 40.81%. Additionally, its Average True Range was 0.05.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 45.83%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.13% in the past 14 days, which was lower than the 71.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7951, while its 200-day Moving Average is $1.0207. Nevertheless, the first resistance level for the watch stands at $0.9228 in the near term. At $0.9456, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9912. If the price goes on to break the first support level at $0.8544, it is likely to go to the next support level at $0.8088. Assuming the price breaks the second support level, the third support level stands at $0.7860.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
Market capitalization of the company is 112.21 million based on 124,616K outstanding shares. Right now, sales total 146,030 K and income totals -143,100 K. The company made 42,790 K in profit during its latest quarter, and 23,790 K in sales during its previous quarter.
